That’s probably all it is—an absurdly low valuation can be a strong catalyst in its own right.
>…so much easier trying to buy "busted" biotechs<
Actually, I don’t consider MNTA busted in terms of its fundamentals. I use that characterization for biotechs who had a major clinical/regulatory failure and have little remaining assets of value other than cash on the balance sheet. MNTA is certainly not in that category.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.